Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)

ClinicalTrials.gov ID

NCT07687706

Lead Sponsor

Hanyang University Guri HospitalOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

1,524Estimated

Last Update Posted

Jul 8, 2026Actual

Start Date

Jan 26, 2026Actual

Primary Completion Date

Jun 2027Estimated

Completion Date

Dec 2027Estimated

Official Title

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Superiority, Investigator-initiated Trial of Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)

Brief Summary

Patients with ischemic stroke commonly receive antiplatelet therapy, frequently starting as dual antiplatelet therapy, which is associated with an increased risk of gastrointestinal complications. Although evidence for gastroprotection is established in coronary artery disease, no comparable guidance or evidence exists for stroke care. Tegoprazan is a potassium-competitive acid blocker offering rapid, meal-independent acid suppression with fewer drug interactions than proton pump inhibitors, yet whether it prevents such complications after stroke remains unknown. Thus, the investigators aim to evaluate whether tegoprazan reduces gastrointestinal complications in patients receiving antiplatelet therapy after ischemic stroke.

TegoStroke is a phase 3, multicenter, randomized, double-blind, placebo-controlled, superiority trial conducted at more than 20 centers in the Republic of Korea. Adult patients who are starting antiplatelet therapy after acute ischemic stroke or transient ischemic attack, and who are expected to continue it for at least 6 months, will be included. Eligible patients will be 1:1 randomized to receive oral tegoprazan 50 mg once daily or matching placebo for 180 days. The primary outcome is a composite of upper or indeterminate-origin gastrointestinal bleeding, gastric or duodenal ulcer ≥3 mm, or erosive esophagitis, ascertained up to a day-180 esophagogastroduodenoscopy. This study would provide the first randomized evidence on routine gastroprotection for patients on antiplatelet therapy after ischemic stroke.

• Ischemic Stroke
• Ischemic Stroke, Acute
• Transient Ischemic Attack (TIA)
• Cerebrovascular Disease
• Gastrointestinal Complication
• Gastrointestinal Bleeding

• Tegoprazan 50 mg
• Placebo

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Age 19 years or older.
2. Hospitalization for acute ischemic stroke or transient ischemic attack, with antiplatelet therapy initiated for the first time, expected to continue for at least 6 months at the treating physician's discretion per relevant stroke guidelines, and within 4 weeks of the first antiplatelet dose at the time of randomization.
3. Written informed consent provided by the participant or a legally authorized representative.
4. Ability and willingness to understand the study procedures described in the consent form and to comply with the study protocol.

Exclusion Criteria:

1. History of peptic ulcer disease diagnosis or gastrointestinal bleeding within the past year. At screening, the history and findings of any EGD performed within the preceding 2 years were obtained by participant interview.
2. Need for concomitant anticoagulant therapy (transient anticoagulation such as argatroban during the index admission is permitted, with randomization after it is stopped)
3. Anticipated difficulty in undergoing gastrointestinal endoscopy during the study period.
4. Use of a P-CAB, PPI, or H2-receptor antagonist within 1 week before randomization, or an active indication for these agents, a mucosal protectant, or an antacid at enrollment. Temporary use of these agents during acute care in the index admission, since discontinued and without a current indication, is not exclusionary.
5. Hypersensitivity or contraindication to a P-CAB or to benzimidazoles.
6. AST, ALT, ALP, or γ-GT ≥5 times the upper limit of normal (ULN), or total bilirubin ≥3 times the ULN at screening.
7. Participation within the past 12 months in any of the following: (1) a clinical study that may affect the efficacy or safety assessments of the present study; (2) a study involving an investigational product or procedure not administered under standard-of-care guidelines; (3) a study that may pose additional risk to the participant. (Participation in other clinical studies is otherwise permitted.)
8. Current use of, or use within five half-lives of, a contraindicated interacting drug (atazanavir, nelfinavir, rilpivirine, and preparations containing these components).
9. Any other condition deemed by the investigators to render the patient unsuitable for study participation, including but not limited to:

Primary Purpose

Prevention

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Triple

Lead Sponsor

Hanyang University Guri HospitalOTHER

Collaborators

HK inno.N CorporationINDUSTRY

ksh213@hanyang.ac.kr

• Tirofiban for the Prevention of Neurological Deterioration in Acute Ischemic Stroke

  NCT04491695

  Unknown statusInterventionalPhase 2Phase 3Updated Jul 19, 2022
• Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs

  NCT04840550

  Unknown statusInterventionalPhase 3Updated Jul 14, 2023
• Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects

  NCT06164834

  Unknown statusInterventionalPhase 1Updated Dec 11, 2023
• Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)

  NCT01612884

  TerminatedInterventionalPhase 4Updated Apr 26, 2018
• Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants

  NCT03814642

  CompletedInterventionalPhase 1Updated Oct 21, 2019
• THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

  NCT03354429

  CompletedInterventionalPhase 3Updated Dec 22, 2020